Drug Profile
Insulin glargine - Sanofi
Alternative Names: HOE-901; HOE71GT; Lantus; Lantus SoloStar; OptisulinLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 31 Dec 2022 Sanofi has later filled patents for the generics and biosimilars on the market, in USA, EU and Japan, prior to December 2022
- 29 Dec 2021 Viatris wins court decisions on Sanofi appeals of insulin glargine patent invalidations
- 29 May 2020 US Patent and Trademark Appeal Board (PTAB) rules in favor of Mylan for patent infringement filed by Sanofi in USA